Preclinical evaluation of ixazomib for high-risk pediatric brain tumors.

Janko E, Walker FM, Slade M, Danis E, Bompada P, Martin Sobral L, Chapman J, Bal S, Link G, McQuillan N, Mulcahy Levy JM, Green AL, Dahl NA

Open source

DOI: 10.64898/2026.09.11.750478
Published: 2026 Sep 18
Container: bioRxiv : the preprint server for biology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.64898/2026.09.11.750478,
  title = {Preclinical evaluation of ixazomib for high-risk pediatric brain tumors.},
  author = {Janko E and Walker FM and Slade M and Danis E and Bompada P and Martin Sobral L and Chapman J and Bal S and Link G and McQuillan N and Mulcahy Levy JM and Green AL and Dahl NA},
  year = {2026},
  journal = {bioRxiv : the preprint server for biology},
  doi = {10.64898/2026.09.11.750478},
  url = {https://doi.org/10.64898/2026.09.11.750478}
}

RIS

TY  - JOUR
TI  - Preclinical evaluation of ixazomib for high-risk pediatric brain tumors.
AU  - Janko E
AU  - Walker FM
AU  - Slade M
AU  - Danis E
AU  - Bompada P
AU  - Martin Sobral L
AU  - Chapman J
AU  - Bal S
AU  - Link G
AU  - McQuillan N
AU  - Mulcahy Levy JM
AU  - Green AL
AU  - Dahl NA
PY  - 2026
JO  - bioRxiv : the preprint server for biology
DO  - 10.64898/2026.09.11.750478
UR  - https://doi.org/10.64898/2026.09.11.750478
ER  -

APA

E, J., FM, W., M, S., E, D., P, B., L, M. S., J, C., S, B., G, L., N, M., JM, M. L., AL, G., & NA, D. (2026). Preclinical evaluation of ixazomib for high-risk pediatric brain tumors.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.09.11.750478

Source records

pubmed · retrieved 2026-09-25T18:17:28.008Z